BioVaxys Technology Corp. (BioVaxys), the advancement of viral and oncology vaccine platforms and immunodiagnostic products, announced the appointment of Adam Coutts , PhD, as Policy Advisor.
Dr. Coutts is a Senior Research Fellow at Magdalene College at the University of Cambridge and a Research Associate in the Department of Sociology at the University of Cambridge . The research focus of Dr. Coutts is on the social and political determinants of health. He examines how public action outside the health sector affects the health and wellbeing of vulnerable groups and how government interventions can be used to help them.
Dr. Coutts received his PhD from the Department of Sociology at the University of Cambridge and received postdoctoral fellowships in Cambridge and on Department of Politics and International Relations, University of Oxford, Nuffield College. Dr. Coutts is also a research fellow at the Center for Business Research, Cambridge .
James Passin , CEO of BioVaxys , said, “We are honored to have Dr. Coutts as BioVaxys Policy Advisor to have by our side. Dr. Coutts ‘expertise and experience in public health policy, bringing together academic, policy-makers and multilateral agencies with those in the field of health care, will prove critical when BioVaxys’ CoviDTH, a novel skin test for T-cell immunity against COVID-19, through which regulatory and commercial development brings. We believe CoviDTH can offer a transformative approach to public health policy in low-income contexts, especially in humanitarian and conflict situations where resources and access are limited. This approach provides governments with a tool to optimize vaccine distribution and targeting.”
Dr. Coutts stated, “CoviDTH offers a cost effective and reliable solution to mitigate the effects of the pandemic in fragile and humanitarian situations where health systems are already under strain and resources and access are difficult. To end the pandemic, everyone, everywhere, needs the protection of affordable and effective products like CoviDTH. “
In Vancouver resident BioVaxys Technology Corp . is a in British Columbia Registered early stage biotechnology company developing viral and oncological vaccine platforms and immunodiagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and plans to conduct a clinical trial of its haptenized autologous cell vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, initially to be developed for ovarian cancer.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.